<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153435</url>
  </required_header>
  <id_info>
    <org_study_id>00002</org_study_id>
    <secondary_id>2019-003387-46</secondary_id>
    <nct_id>NCT04153435</nct_id>
  </id_info>
  <brief_title>Calcium for Out-of-Hospital Cardiac Arrest</brief_title>
  <acronym>COCA</acronym>
  <official_title>Calcium for Out-of-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Wiuff Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Central Denmark Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel&#xD;
      group, double-blind, superiority trial of calcium during adult out-of-hospital cardiac&#xD;
      arrest. 430 adult patients with out-of-hospital cardiac arrest receiving at least one dose of&#xD;
      adrenaline will be enrolled. The primary outcome is sustained return of spontaneous&#xD;
      circulation and key secondary outcomes include survival at 30 days and survival at 30 days&#xD;
      with a favorable neurological outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained return of spontaneous circulation</measure>
    <time_frame>Before or after hospital arrival (up to 2 hours after the cardiac arrest)</time_frame>
    <description>Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days after the cardiac arrest</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable neurological outcome</measure>
    <time_frame>30 days after the cardiac arrest</time_frame>
    <description>Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Heart Arrest, Out-Of-Hospital</condition>
  <arm_group>
    <arm_group_label>Calcium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, &quot;normal saline&quot;) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Chloride</intervention_name>
    <description>Calcium chloride 5 mmol</description>
    <arm_group_label>Calcium</arm_group_label>
    <other_name>CaCl2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Out-of-hospital cardiac arrest&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Received at least one dose of adrenaline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Traumatic cardiac arrest - including drowning and external asphyxia (e.g., hanging,&#xD;
             strangulation, or foreign object airway obstruction)&#xD;
&#xD;
          -  Known or strongly suspected pregnancy&#xD;
&#xD;
          -  Prior enrollment in the trial&#xD;
&#xD;
          -  Received adrenaline during cardiac arrest before arrival of prehospital personnel with&#xD;
             the study drug&#xD;
&#xD;
          -  Clinical indication for calcium administration during the cardiac arrest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars W Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prehospital Emergency Medical Services</name>
      <address>
        <city>Aarhus N</city>
        <state>Central Denmark Region</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.cocatrial.dk</url>
    <description>Trial website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Wiuff Andersen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Six months after the publication of the last results, all deidentified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete deidentification of the data. Data will be completely anonymized according to Danish law.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Six months after the publication of the last results</ipd_time_frame>
    <ipd_access_criteria>Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

